Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 5, 1997New England Journal of Medicine

Multiple Myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

RBRégis BatailleUniversité d'AngersJHJean‐Luc HarousseauInstitut de Cancérologie de l'Ouest

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Bataille et al. (1997) studied this question.

synapsesocial.com/papers/6a0da2326e03bc61cb09d733https://doi.org/10.1056/nejm199706053362307
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma1993 · 73 citations
  2. 2The growth fraction of human myeloma cells1981 · 138 citations
  3. 3Prognostic factors with high-dose melphalan for refractory multiple myeloma [see comments]1988 · 37 citations
  4. 4Effect of interferon on the health‐related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan–prednisone to melphalan–prednisone + α‐interferon1996 · 73 citations
  5. 5Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.1994 · 135 citations